Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache

Tonix Pharmaceuticals

Status and phase

Completed

Phase 2

Conditions

Tension-Type Headache

Treatments

Drug: Placebo

Drug: TNX-201

Study type

Interventional

Funder types

Industry

Identifiers

NCT02423408

TNX-IS-T201

Details and patient eligibility

About

This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of a single dose of TNX-201 (140 mg) for the treatment of a single qualifying Tension-Type-Headache (TTH).

Full description

The study will be conducted in 4 periods (the Screening Period, the Run-In Period, the Double-Blind Treatment Period and the Follow-up Period) and 4 visits (the Screening Visit, Enrollment Visit, Randomization Visit and End-of-Study Visit).

Screening Period- Eligible subjects who provide written informed consent to participate will have study assessments performed at the Screening.

Run-In Period- The Run-In Period will last for at least 28 days. During the Run-In period, subjects will be assessed for frequency of headache, study compliance and to ensure they meet all required study criteria for randomization.

Double-Blind Treatment Period- The Double-Blind Treatment Period (Treatment Period) will last up to 4 weeks or until a qualifying headache episode has occurred and been treated using the study drug, whichever occurs first.

Follow-up Period- All subjects will return to the investigational site for this visit, regardless of whether they have treated a qualifying TTH with study medication. Subjects who have not treated a qualifying TTH with study drug during the Treatment Period will be asked to return study materials and undergo safety evaluations at the End-of-Study Visit and will be discharged from the study. Subjects who have treated a qualifying TTH with study drug during the Treatment Period will ingest a 140 mg dose of open-label TNX-201 at this visit and undergo urine and blood sample collection for 3 hours post-dose to characterize each subject's genetic metabolism and PK profile.

Enrollment

165 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Capable of reading and understanding English and able to provide written informed consent to participate.
Male or female adults ≥ 18 and < 65 years of age at the time of Visit 1.
Body mass index (BMI) ≥ 18.5 and ≤ 45.0.
Greater than 1 year history of episodic tension-type headache with onset prior to 50 years of age.
History of tension-type headaches that typically last ≥ 4 hours if untreated.
History of 2-14 tension-type headaches per month for the last 3 months prior to Visit 1.
Diagnosis must comply with the International Headache Society (IHS) diagnostic criteria.
No significant ECG findings at Screening
If female, is either not of childbearing potential or is practicing a predefined medically acceptable method of birth control (hormonal methods, intrauterine device, double-barrier method, sexually-exclusive vasectomized male partner, same-sex relationship) throughout the study.
Willing and able to comply with all protocol-specified requirements.

Exclusion criteria

Known or suspected hypersensitivity to isometheptene mucate or any excipients used in the formulation.
Use of any excluded concomitant medications.
Current use of opiate analgesics.
Use of any prophylactic drug therapy for headache control within 4 weeks of screening (e.g., anticonvulsants, mood stabilizers, beta-blocker, antidepressants, muscle relaxants, botulinum toxin). Subjects taking any of these medications for an indication other than headache (e.g., a beta-blocker for hypertension) will require medical monitor's approval prior to initiation of the Run-In Period.
History of medication use for acute headache on ≥ 10 days per month on average during the 3 months prior to Visit 1.
Positive results for addictive substances (e.g., cocaine, phencyclidine (PCP), amphetamines, opiates) at Screening.
History of migraine that exceeds a mean of four attacks per month during the preceding calendar year.
Lifetime history of schizophrenia, schizoaffective disorder, bipolar I/II disorder, delusional disorder, or psychotic disorder not otherwise specified.
Chronic pain disorders requiring medical treatment with opioids, chronic daily use of NSAIDs at the time of screening
History of coronary artery disease, coronary vasospasm, aortic aneurysm, peripheral vascular disease or other ischemic diseases (e.g., ischemic bowel syndrome or Raynaud's syndrome).
Inadequately controlled hypertension or persistently elevated systolic blood pressure or diastolic blood pressure upon repeat assessment at screening or on the day of randomization.
Current history of two or more CAD risk factors at Screening (tobacco use, receiving anti-hypertensive medication for hypertension, high LDL cholesterol or low HDL cholesterol levels, family history of premature CAD, diabetes mellitus)
History cerebral vascular accident, transient ischemic attack, seizure disorders.
Other clinically significant cardiac disease.
History of concurrent illness that requires hospitalization within 30 days prior to Visit 1.
Current evidence of human immunodeficiency virus infection or clinically significant hepatitis B or C infection.
Clinically significant laboratory abnormalities based on screening laboratory tests and/or medical history.
Participation in another investigational trial during the 30 days prior to Visit 1 or during this trial. Subjects who have participated in non-interventional trials may be permitted to participate on a case-by-case basis after review with the Medical Monitor.
Women who are pregnant, breast-feeding, or planning to become pregnant during this trial.
Any other household member currently participating in a Tonix-sponsored study or family member or relative of investigative staff.
Any condition and/or medical history that would make the subject unsuitable for study participation and completion.